HUMACYTE INC. - COMMON STOCK

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

31 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

17 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in May

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte First Quarter 2024 Financial Results and Business Update

10 May 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

26 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

22 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

01 Mar 2024 08:16:19 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

29 Feb 2024 20:18:05 By Nasdaq GlobeNewswire

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

29 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

09 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

24 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

17 Nov 2023 07:00:00 By Nasdaq GlobeNewswire